share_log

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga ·  Oct 7, 2023 05:31

Gainers

  • ContraFect (NASDAQ:CFRX) stock rose 17.5% to $0.47 during Friday's after-market session. The market value of their outstanding shares is at $2.5 million.
  • Exagen (NASDAQ:XGN) shares rose 15.63% to $2.44. The market value of their outstanding shares is at $41.1 million.
  • Pasithea Therapeutics (NASDAQ:KTTA) stock rose 15.0% to $0.46. The market value of their outstanding shares is at $9.5 million.
  • Talaris Therapeutics (NASDAQ:TALS) stock moved upwards by 10.25% to $2.98. The market value of their outstanding shares is at $130.8 million.
  • Renalytix (NASDAQ:RNLX) stock moved upwards by 8.94% to $1.34. This security traded at a volume of 67.0K shares come close, making up 56.8% of its average volume over the last 100 days. The company's market cap stands at $63.6 million.
  • GRI Bio (NASDAQ:GRI) stock moved upwards by 8.85% to $1.72. The market value of their outstanding shares is at $5.0 million.

Losers

  • Addex Therapeutics (NASDAQ:ADXN) shares declined by 10.8% to $0.38 during Friday's after-market session. At the close, Addex Therapeutics's trading volume reached 609.2K shares. This is 1094.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $6.0 million.
  • Dyadic International (NASDAQ:DYAI) shares decreased by 9.81% to $1.84. The company's market cap stands at $53.0 million.
  • Sunshine Biopharma (NASDAQ:SBFM) shares decreased by 9.47% to $0.33. The market value of their outstanding shares is at $8.4 million.
  • Senti Biosciences (NASDAQ:SNTI) stock fell 6.6% to $0.34. The company's market cap stands at $15.1 million.
  • First Wave BioPharma (NASDAQ:FWBI) stock decreased by 5.55% to $0.31. The company's market cap stands at $4.1 million.
  • Salarius Pharmaceuticals (NASDAQ:SLRX) shares fell 5.17% to $0.62. The company's market cap stands at $2.2 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment